$CASI制药(CASI)$
• CASI Pharmaceuticals (NASDAQ:CASI) has received National Medical Products Administration ("NMPA") approval of Melphalan Hydrochloride For Injection (EVOMELA®), for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma, and
• The palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
• The approval was based on an existing safety and efficacy data base; the NMPA required no additional pre-approval clinical studies, but requires a post approval confirmatory study.
• Shares are up 7% premarket